(Novartis Signature) Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 4 - LGX818 for patients with BRAFV600 mutated tumors

Diseases and Conditions Researched

Bladder; Brain and Nervous System; Breast - Female; Esophagus; Eye and Orbit; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, skin; Other Skin; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach

What is the purpose of this trial?

To assess clinical benefit associated with LGX818 treatment based on local investigator assessment.

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Novartis Pharmaceuticals
Last Updated:
Study HIC#: 1406014167